Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-β1a in monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 1, 2003, Pages 262-270

  Mager, Donald E ^a,d   Neuteboom, Berend ^b   Efthymiopoulos, Constantinos ^c   Munafo, Alain ^c   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b Istituto di Ricerche Biomediche Antoine Marxer SpA   (Italy)

^c Serono International SA   (Switzerland)

^d NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; NEOPTERIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; INTERNALIZATION; MALE; MONKEY; NONHUMAN; NONLINEAR SYSTEM; PRIORITY JOURNAL; RECEPTOR BINDING;

ANIMALS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INTERFERON-BETA; MACACA FASCICULARIS; MALE; NEOPTERIN;

EID: 0038679559     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.049502     Document Type: Article

References (35)

1. Alam J, Goelz S, Rioux P, Scaramucci J, Jones W, McAllister A, Campion M, and Rogge M (1997) Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferonβ-1a (IFN β-1a) products administered intramuscularly in healthy male and female volunteers. Pharm Res (NY) 14:546-549.
2. Buchwalder PA, Buclin T, Trinchard I, Munafo A, and Biollaz J (2000) Pharmacokinetics and pharmacodynamics of IFN-β1a in healthy volunteers. J Interferon Cytokine Res 20:857-866.
3. Buraglio M, Trinchard-Lugan I, Munafo A, and Macnamee M (1999) Recombinant human interferon-β-1a (Rebif®) vs recombinant interferon-β-1b (Betaseron®) in healthy volunteers. A pharmacodynamic and tolerability study. Clin Drug Investig 18:27-34.
4. Cheng H, Staubus A, and Shum L (1988) An area function method for estimating the apparent absorption rate constant. Pharm Res (NY) 5:57-60.
5. Chiang J, Gloff CA, Yoshizawa CN, and Williams GJ (1993) Pharmacokinetics of recombinant human interferon-β ser in healthy volunteers and its effect on serum neopterin. Pharm Res (NY) 10:567-572.
6. D'Argenio DZ and Schumitzky A (1997) ADAPT II User's Guide, Biomedical Simulations Resource, Los Angeles.
7. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10:1093-1095.
8. Dayneka NL, Garg V, and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
9. Fierlbeck G, Ulmer A, Schreiner T, Stroebel W, Schiebel U, and Brzoska J (1996) Pharmacodynamics of recombinant IFN-β during long-term treatment of malignant melanoma. J Interferon Cytokine Res 16:777-781.
10. Fuchs D, Weiss G, Reibnegger G, and Wachter H (1992) The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit Rev Clin Lab Sci 29:307-341.
11. Gloff C and Wills R (1992) Pharmacokinetics and metabolism of therapeutic cytokines, in Protein Pharmacokinetics and Metabolism (Ferraiolo B, Mohler M, and Gloff C eds) pp 127-150, Plenum Press, New York.
12. Gobburu J and Jusko W (1998) Role of dosage regimen in controlling indirect pharmacodynamic responses. Adv Drug Delivery Rev 33:221-233.
13. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, and van den Noort S (2002) Disease modifying therapies in multiple sclerosis. Neurology 58:169-178.
14. Jusko WJ (1992) Guidelines for collection and analysis of pharmacokinetic data, in Applied Pharmacokinetics (Evans WE, Schentag JJ, and Jusko WJ eds) chapter 2, Applied Therapeutics, Inc., Vancouver, BC, Canada.
15. Kang W and Weiss M (2002) Digoxin uptake, receptor heterogeneity and inotropic response in the isolated rat heart: a comprehensive kinetic model. J Pharmacol Exp Ther 302:577-583.
16. Leonard W (1999) Type I cytokines and interferons and their receptors, in Fundamental Immunology (Paul Wed) pp 741-774, Lippincott-Raven, Philadelphia.
17. Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248-252.
18. Liberati AM, Fizzotti M, Proietti MG, Di Marzio R, Schippa M, Biscottini B, Senatore M, Berruto P, Canali S, Peretti G, et al. (1988) Biochemical host response to interferon-β. J Interferon Res 8:765-777.
19. Mager DE and Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532.
20. Mager DE and Jusko WJ (2002) Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-β1a in humans. Pharm Res (NY) 19:1537-1543.
21. Munafo A, Trinchard-Lugan I, Nguyen TXQ, and Buraglio M (1998) Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon β-1a after intramuscular and subcutaneous administration. Eur J Neurol 5:187-193.
22. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, Baker DP, Whalley E, Hochman PS, and Martin P (2001) Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 297:1059-1066.
23. Pestka S, Langer JA, Zoon KC, and Samuel CE (1987) Interferons and their actions. Annu Rev Biochem 56:727-777.
24. Radwanski E, Chakraborty A, Van Wart S, Huhn RD, Cutler DL, Affrime MB, and Jusko WJ (1998) Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res (NY) 15:1895-1901.
25. Rothuizen LE, Buclin T, Spertini F, Trinchard I, Munafo A, Buchwalder PA, Ythier A, and Biollaz J (1999) Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 99:131-141.
26. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, and Darragh A (1996) Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J Interferon Cytokine Res 16:759-764.
27. Sharma A, Ebling WF, and Jusko WJ (1998) Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 87:1577-1584.
28. Stark G, Kerr I, Williams B, Silverman R, and Schreiber R (1998) How cells respond to interferons. Annu Rev Biochem 67:227-264.
29. Sugiyama Y and Hanano M (1989) Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm Res (NY) 6:192-202.
30. Sun YN, DuBois DC, Almon RR, and Jusko WJ (1998) Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine amino-transferase induction in rat liver. J Pharmacokinet Biopharm 26:289-317.
31. Supersaxo A, Hein W, and Steffen H (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res (NY) 7:167-169.
32. Williams GJ and Witt PL (1998) Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. J Interferon Cytokine Res 18:967-975.
33. Wills R (1990) Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19:390-399.
34. Yong VW, Chabot S, Stuve O, and Williams G (1998) Interferon β in the treatment of multiple sclerosis: mechanisms of action. Neurology 51:682-689.
35. Zoon KC and Arnheiter H (1984) Studies of the interferon receptors. Pharmacol Ther 24:259-278.